Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Diagnosis, Phenotype, and Molecular Genetics of Congenital Analbuminemia.

Minchiotti L, Caridi G, Campagnoli M, Lugani F, Galliano M, Kragh-Hansen U.

Front Genet. 2019 Apr 17;10:336. doi: 10.3389/fgene.2019.00336. eCollection 2019. Review.

2.

Possible Mechanisms by Which Enzymatic Degradation of Human Serum Albumin Can Lead to Bioactive Peptides and Biomarkers.

Kragh-Hansen U.

Front Mol Biosci. 2018 Jul 9;5:63. doi: 10.3389/fmolb.2018.00063. eCollection 2018.

3.

Clinical, Genetic, and Protein Structural Aspects of Familial Dysalbuminemic Hyperthyroxinemia and Hypertriiodothyroninemia.

Kragh-Hansen U, Galliano M, Minchiotti L.

Front Endocrinol (Lausanne). 2017 Nov 1;8:297. doi: 10.3389/fendo.2017.00297. eCollection 2017. Review.

4.

N-acetyl-L-methionine is a superior protectant of human serum albumin against post-translational oxidation as compared to N-acetyl-L-tryptophan.

Kouno Y, Anraku M, Yamasaki K, Okayama Y, Iohara D, Nakamura H, Maruyama T, Hirayama F, Kragh-Hansen U, Otagiri M.

Biochem Biophys Rep. 2016 Apr 26;6:266-274. doi: 10.1016/j.bbrep.2016.04.011. eCollection 2016 Jul.

5.

An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing.

Bienk K, Hvam ML, Pakula MM, Dagnæs-Hansen F, Wengel J, Malle BM, Kragh-Hansen U, Cameron J, Bukrinski JT, Howard KA.

J Control Release. 2016 Jun 28;232:143-51. doi: 10.1016/j.jconrel.2016.04.013. Epub 2016 Apr 12.

PMID:
27084489
6.

Mutants and molecular dockings reveal that the primary L-thyroxine binding site in human serum albumin is not the one which can cause familial dysalbuminemic hyperthyroxinemia.

Kragh-Hansen U, Minchiotti L, Coletta A, Bienk K, Galliano M, Schiøtt B, Iwao Y, Ishima Y, Otagiri M.

Biochim Biophys Acta. 2016 Apr;1860(4):648-60. doi: 10.1016/j.bbagen.2016.01.001. Epub 2016 Jan 8.

PMID:
26777880
7.

S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.

Kinoshita R, Ishima Y, Ikeda M, Kragh-Hansen U, Fang J, Nakamura H, Chuang VT, Tanaka R, Maeda H, Kodama A, Watanabe H, Maeda H, Otagiri M, Maruyama T.

J Control Release. 2015 Nov 10;217:1-9. doi: 10.1016/j.jconrel.2015.08.036. Epub 2015 Aug 22.

PMID:
26302904
8.

Nitration of indoxyl sulfate facilitates its cytotoxicity in human renal proximal tubular cells via expression of heme oxygenase-1.

Ishima Y, Narisoko T, Kragh-Hansen U, Kotani S, Nakajima M, Otagiri M, Maruyama T.

Biochem Biophys Res Commun. 2015 Sep 25;465(3):481-7. doi: 10.1016/j.bbrc.2015.08.043. Epub 2015 Aug 13.

PMID:
26277392
9.

Amino acids of importance for the antioxidant activity of human serum albumin as revealed by recombinant mutants and genetic variants.

Anraku M, Shintomo R, Taguchi K, Kragh-Hansen U, Kai T, Maruyama T, Otagiri M.

Life Sci. 2015 Aug 1;134:36-41. doi: 10.1016/j.lfs.2015.05.010. Epub 2015 May 30.

PMID:
26032253
10.

Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine.

Ishima Y, Fang J, Kragh-Hansen U, Yin H, Liao L, Katayama N, Watanabe H, Kai T, Suenaga A, Maeda H, Otagiri M, Maruyama T.

J Pharm Sci. 2014 Jul;103(7):2184-2188. doi: 10.1002/jps.24020. Epub 2014 May 20.

PMID:
24846171
11.

N-acetyl-l-methionine is a superior protectant of human serum albumin against photo-oxidation and reactive oxygen species compared to N-acetyl-L-tryptophan.

Kouno Y, Anraku M, Yamasaki K, Okayama Y, Iohara D, Ishima Y, Maruyama T, Kragh-Hansen U, Hirayama F, Otagiri M.

Biochim Biophys Acta. 2014 Sep;1840(9):2806-12. doi: 10.1016/j.bbagen.2014.04.014. Epub 2014 Apr 22.

PMID:
24769178
12.

Poly-s-nitrosated albumin as a safe and effective multifunctional antitumor agent: characterization, biochemistry and possible future therapeutic applications.

Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M.

Biomed Res Int. 2013;2013:353892. doi: 10.1155/2013/353892. Epub 2013 Dec 30. Review.

13.

Congenital analbuminaemia: molecular defects and biochemical and clinical aspects.

Minchiotti L, Galliano M, Caridi G, Kragh-Hansen U, Peters T Jr.

Biochim Biophys Acta. 2013 Dec;1830(12):5494-502. doi: 10.1016/j.bbagen.2013.04.019. Epub 2013 Apr 21. Review.

PMID:
23612153
14.

Human serum albumin isoforms: genetic and molecular aspects and functional consequences.

Kragh-Hansen U, Minchiotti L, Galliano M, Peters T Jr.

Biochim Biophys Acta. 2013 Dec;1830(12):5405-17. doi: 10.1016/j.bbagen.2013.03.026. Epub 2013 Apr 2. Review.

PMID:
23558059
15.

Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes.

Kragh-Hansen U.

Biochim Biophys Acta. 2013 Dec;1830(12):5535-44. doi: 10.1016/j.bbagen.2013.03.015. Epub 2013 Mar 23. Review.

PMID:
23528895
16.

UW solution improved with high anti-apoptotic activity by S-nitrosated human serum albumin.

Ishima Y, Shinagawa T, Yoneshige S, Kragh-Hansen U, Ohya Y, Inomata Y, Kai T, Otagiri M, Maruyama T.

Nitric Oxide. 2013 Apr 1;30:36-42. doi: 10.1016/j.niox.2013.01.004. Epub 2013 Feb 9.

PMID:
23402724
17.

Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment.

Minomo A, Ishima Y, Chuang VT, Suwa Y, Kragh-Hansen U, Narisoko T, Morioka H, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2013 Apr;1830(4):2917-23. doi: 10.1016/j.bbagen.2013.01.006. Epub 2013 Jan 15.

PMID:
23328494
18.

Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models.

Ishima Y, Hara M, Kragh-Hansen U, Inoue A, Suenaga A, Kai T, Watanabe H, Otagiri M, Maruyama T.

J Control Release. 2012 Nov 28;164(1):1-7. doi: 10.1016/j.jconrel.2012.10.003. Epub 2012 Oct 11.

PMID:
23063551
19.

S-guanylation of human serum albumin is a unique posttranslational modification and results in a novel class of antibacterial agents.

Ishima Y, Hoshino H, Shinagawa T, Watanabe K, Akaike T, Sawa T, Kragh-Hansen U, Kai T, Watanabe H, Maruyama T, Otagiri M.

J Pharm Sci. 2012 Sep;101(9):3222-9. doi: 10.1002/jps.23143. Epub 2012 Apr 4.

PMID:
22488009
20.

Quantitative evaluation of the role of cysteine and methionine residues in the antioxidant activity of human serum albumin using recombinant mutants.

Iwao Y, Ishima Y, Yamada J, Noguchi T, Kragh-Hansen U, Mera K, Honda D, Suenaga A, Maruyama T, Otagiri M.

IUBMB Life. 2012 May;64(5):450-4. doi: 10.1002/iub.567. Epub 2012 Feb 20.

21.

S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects.

Ishima Y, Chen D, Fang J, Maeda H, Minomo A, Kragh-Hansen U, Kai T, Maruyama T, Otagiri M.

Bioconjug Chem. 2012 Feb 15;23(2):264-71. doi: 10.1021/bc2005363. Epub 2012 Jan 20.

PMID:
22225412
22.

Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXα revealed by phage display.

Minomo A, Ishima Y, Kragh-Hansen U, Chuang VT, Uchida M, Taguchi K, Watanabe H, Maruyama T, Morioka H, Otagiri M.

FEBS J. 2011 Nov;278(21):4100-11. doi: 10.1111/j.1742-4658.2011.08316.x. Epub 2011 Sep 23.

23.

Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin.

Ishima Y, Yoshida F, Kragh-Hansen U, Watanabe K, Katayama N, Nakajou K, Akaike T, Kai T, Maruyama T, Otagiri M.

Free Radic Res. 2011 Oct;45(10):1196-206. doi: 10.3109/10715762.2011.606814. Epub 2011 Aug 16.

PMID:
21781009
24.

One-step preparation of S-nitrosated human serum albumin with high biological activities.

Ishima Y, Hiroyama S, Kragh-Hansen U, Maruyama T, Sawa T, Akaike T, Kai T, Otagiri M.

Nitric Oxide. 2010 Sep 15;23(2):121-7. doi: 10.1016/j.niox.2010.05.002. Epub 2010 May 6.

PMID:
20451647
25.

Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin.

Hein KL, Kragh-Hansen U, Morth JP, Jeppesen MD, Otzen D, Møller JV, Nissen P.

J Struct Biol. 2010 Sep;171(3):353-60. doi: 10.1016/j.jsb.2010.03.014. Epub 2010 Mar 27.

PMID:
20347991
26.

Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications.

Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M.

Drug Metab Pharmacokinet. 2009;24(4):308-17.

27.

Albumins with new functions and clinical applications.

Otagiri M, Kragh-Hansen U, Imai T.

Drug Metab Pharmacokinet. 2009;24(4):285-6. No abstract available.

28.

Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin.

Iwao Y, Hiraike M, Kragh-Hansen U, Kawai K, Suenaga A, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2009 Apr;1794(4):634-41. doi: 10.1016/j.bbapap.2008.11.022. Epub 2008 Dec 8.

PMID:
19110077
29.

S-nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding.

Ishima Y, Akaike T, Kragh-Hansen U, Hiroyama S, Sawa T, Suenaga A, Maruyama T, Kai T, Otagiri M.

J Biol Chem. 2008 Dec 12;283(50):34966-75. doi: 10.1074/jbc.M807009200. Epub 2008 Oct 20.

30.

[Human serum albumin: gene-technological possibilities].

Kragh-Hansen U.

Ugeskr Laeger. 2008 Sep 15;170(38):2958-62. Review. Danish.

PMID:
18808748
31.

[Human serum albumin: isoforms and analbuminemia].

Kragh-Hansen U.

Ugeskr Laeger. 2008 May 5;170(19):1638-43. Review. Danish.

PMID:
18489873
32.

Mutations and polymorphisms of the gene of the major human blood protein, serum albumin.

Minchiotti L, Galliano M, Kragh-Hansen U, Peters T Jr.

Hum Mutat. 2008 Aug;29(8):1007-16. doi: 10.1002/humu.20754.

PMID:
18459107
33.

Effects of endogenous ligands on the biological role of human serum albumin in S-nitrosylation.

Ishima Y, Akaike T, Kragh-Hansen U, Hiroyama S, Sawa T, Maruyama T, Kai T, Otagiri M.

Biochem Biophys Res Commun. 2007 Dec 28;364(4):790-5. doi: 10.1016/j.bbrc.2007.10.094. Epub 2007 Oct 26.

PMID:
18273439
34.

Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin.

Iwao Y, Hiraike M, Kragh-Hansen U, Mera K, Noguchi T, Anraku M, Kawai K, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2007 Dec;1774(12):1582-90. Epub 2007 Sep 19.

PMID:
18029235
35.

[Human serum albumin: news about an old acquaintance].

Kragh-Hansen U.

Ugeskr Laeger. 2007 Oct 8;169(41):3467-70. Review. Danish.

PMID:
17967273
36.

S-Nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties.

Ishima Y, Sawa T, Kragh-Hansen U, Miyamoto Y, Matsushita S, Akaike T, Otagiri M.

J Pharmacol Exp Ther. 2007 Mar;320(3):969-77. Epub 2006 Nov 29.

PMID:
17135341
37.

Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis.

Kragh-Hansen U, Watanabe H, Nakajou K, Iwao Y, Otagiri M.

J Mol Biol. 2006 Oct 27;363(3):702-12. Epub 2006 Aug 25.

PMID:
16979183
38.

Oxidation of Arg-410 promotes the elimination of human serum albumin.

Iwao Y, Anraku M, Yamasaki K, Kragh-Hansen U, Kawai K, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2006 Apr;1764(4):743-9. Epub 2006 Jan 30.

PMID:
16497569
39.

Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites.

Ma SF, Anraku M, Iwao Y, Yamasaki K, Kragh-Hansen U, Yamaotsu N, Hirono S, Ikeda T, Otagiri M.

Drug Metab Dispos. 2005 Dec;33(12):1911-9. Epub 2005 Sep 23.

PMID:
16183779
40.

Detergent binding as a sensor of hydrophobicity and polar interactions in the binding cavities of proteins.

Peyre V, Lair V, André V, le Maire G, Kragh-Hansen U, le Maire M, Møller JV.

Langmuir. 2005 Sep 13;21(19):8865-75.

PMID:
16142972
41.

How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases?

Kawasaki CI, Nishi R, Uekihara S, Hayano S, Kragh-Hansen U, Kawasaki CI, Otagiri M.

Clin Toxicol (Phila). 2005;43(2):95-9.

PMID:
15822760
42.

Rate-of-dialysis technique: theoretical and practical aspects.

Kragh-Hansen U, Dørge E, Pedersen AO.

Anal Biochem. 2005 May 1;340(1):145-53.

PMID:
15802140
43.

Effect of genetic variation on the thermal stability of human serum albumin.

Kragh-Hansen U, Saito S, Nishi K, Anraku M, Otagiri M.

Biochim Biophys Acta. 2005 Feb 14;1747(1):81-8. Epub 2004 Oct 19.

PMID:
15680241
44.

Structural analysis and fatty acid-binding properties of two Croatian variants of human serum albumin.

Kragh-Hansen U, Campagnoli M, Dodig S, Nielsen H, Benko B, Raos M, Cesati R, Sala A, Galliano M, Minchiotti L.

Clin Chim Acta. 2004 Nov;349(1-2):105-12.

PMID:
15469862
45.

Characterization of site I of human serum albumin using spectroscopic analyses: locational relations between regions Ib and Ic of site I.

Yamasaki K, Maruyama T, Takadate A, Suenaga A, Kragh-Hansen U, Otagiri M.

J Pharm Sci. 2004 Dec;93(12):3004-12.

PMID:
15468330
46.

Stabilizing mechanisms in commercial albumin preparations: octanoate and N-acetyl-L-tryptophanate protect human serum albumin against heat and oxidative stress.

Anraku M, Tsurusaki Y, Watanabe H, Maruyama T, Kragh-Hansen U, Otagiri M.

Biochim Biophys Acta. 2004 Oct 1;1702(1):9-17.

PMID:
15450846
47.

Esterase-like activity of serum albumin: characterization of its structural chemistry using p-nitrophenyl esters as substrates.

Sakurai Y, Ma SF, Watanabe H, Yamaotsu N, Hirono S, Kurono Y, Kragh-Hansen U, Otagiri M.

Pharm Res. 2004 Feb;21(2):285-92.

PMID:
15032310
48.

Circular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen.

Yamasaki K, Rahman MH, Tsutsumi Y, Maruyama T, Ahmed S, Kragh-Hansen U, Otagiri M.

AAPS PharmSciTech. 2000 May 14;1(2):E12.

49.

Structural analysis, fatty acid and thyroxine binding properties of Vancouver and Naskapi variants of human serum albumin.

Campagnoli M, Kragh-Hansen U, Overgaard Pedersen A, Amoresano A, Lyon AW, Cesati R, Sala A, Romano A, Galliano M, Minchiotti L.

Clin Biochem. 2003 Nov;36(8):597-605.

PMID:
14636873
50.

The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants.

Nakajou K, Watanabe H, Kragh-Hansen U, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2003 Oct 13;1623(2-3):88-97.

PMID:
14572906

Supplemental Content

Loading ...
Support Center